Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human Dose Escalation study of CD3-CD123 in Patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome

Trial Profile

First-in-human Dose Escalation study of CD3-CD123 in Patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs CD3-CD123 bispecific antibodies-Sanofi (Primary)
  • Indications Acute myeloid leukaemia; B-cell leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 04 Jul 2018 New trial record
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top